Objectives: Vancomycin-resistant enterococci (VRE), particularly vancomycin-resistant Enterococcus faecium (VREfm), have emerged among the leading pathogens causing hospital-acquired infections worldwide. We aimed to examine whether there were newly introduced clones contributing to this increase and to assess the risk factors for mortality in patients with VREfm bacteraemia.
Introduction
Vancomycin-resistant enterococci (VRE) were first reported in 1986. 1, 2 Since then, VRE have emerged as among the most important pathogens causing hospital-acquired infections, especially among patients in intensive care units. 3 Among the VRE isolates causing nosocomial infections, the most common is Enterococcus faecium, followed by Enterococcus faecalis. 4 Infections due to VRE have been shown to be associated with significant in-hospital mortality and morbidity. 5 On the clinical spectrum of VRE infections, bacteraemia is of great concern because the case fatality rate is as high as 40%. 6 Because different VRE strains differ in their ability to cause epidemics of nosocomial infections, molecular typing to differentiate between VRE strains has become increasingly important. 3 Multilocus sequence typing (MLST) has been developed to identify the clonal complexes (CCs) within bacterial populations and used successfully for epidemiological analysis for various bacteria, including enterococci. 7 In Taiwan, a VRE isolate was first identified in 1996. 8 From the surveillance data of nosocomial infections in our hospital, the proportion of VRE among all enterococci was estimated to be 2%-6% between January 2000 and November 2007. However, the proportion increased rapidly to 8.1% in December 2007 and to 14.5% in 2008; this increase was attributed to the emergence of vancomycin-resistant E. faecium (VREfm) (J. T. Wang, unpublished data). A previous study showed that the continuously increasing use of glycopeptides, extended-spectrum cephalosporins, b-lactam/b-lactamase inhibitors and carbapenems in our hospital was temporally associated with the increase in VRE between 2000 and 2009. However, the increase in VRE prevalence was greatest from 2007 to 2009 but small from 2000 to 2007. 9 Therefore, it is unclear why the VRE prevalence remained relatively stable between 2000 and 2007, when the use of these antibiotics increased significantly in our hospital. The policy of nosocomial infection control was not changed during this period, and the incidences of nosocomial infections by other antibiotic-resistant bacteria, including methicillin-resistant Staphylococcus aureus and extensively resistant Acinetobacter baumannii, were decreasing. Because the introduction of new VRE strains into an institute can lead to an increase in VRE infection, 3 the aim of this study was to examine whether there were newly introduced VREfm strains that might have contributed to this increase and to assess the risk factors for all-cause mortality from bacteraemia caused by VREfm.
Methods

Study design, patients and bacterial isolates
This retrospective cohort study was conducted at the National Taiwan University Hospital (NTUH), a major tertiary medical centre in northern Taiwan. The patients were identified by retrieval from the computerized database established by the Infection Control Center of NTUH. Medical records of the patients who were aged ≥20 years and had VRE bacteraemia between January 2003 and December 2010 were reviewed. Patients who had ever developed VRE bacteraemia before the study period were excluded. If patients developed several episodes of VRE bacteraemia during the study period, only the first episode was investigated. The analyses of clinical features, outcomes and genotyping of VRE isolates were focused on those patients with VREfm bacteraemia.
VRE bacteraemia was defined as the growth of VRE in more than one blood culture from a patient with fever (body temperature ≥388C). 10 The blood isolates were preserved for subsequent microbiological characterization. VRE was defined as an Enterococcus isolate with an MIC of vancomycin ≥32 mg/L. The term 'appropriate antibiotic treatment' was defined as the use of those antibiotics that demonstrated activity against VRE isolates according to in vitro susceptibility test results. A standardized case report form was used to collect information on the patients' demographic, clinical and routine laboratory data, which included age, sex, primary focus of VRE bloodstream infections (BSIs), severity of infection (Pitt bacteraemia score), 11 Charlson comorbidity index 12 and the use of immunosuppressants at the onset of VRE bacteraemia. Laboratory data recorded 24 h before and/or after onset of VRE bacteraemia included levels of albumin, C-reactive protein, serum creatinine, aminotransferases, haemoglobin, leucocyte count and platelet count. Leucopenia was defined as a white blood cell count ,4000/mL and thrombocytopenia as a platelet count ,150000/mL. The endpoints were all-cause mortalities within 14 and 28 days from VRE bacteraemia. This study was approved by the Research Ethics Committee at NTUH (NTUH-200812081R).
Antibiotic susceptibility tests
The MICs of various antibiotics for E. faecium, including penicillin, ampicillin, minocycline, erythromycin, ciprofloxacin, rifampin, vancomycin, teicoplanin, linezolid and tigecycline, were determined using the agar dilution method, 13 while that of daptomycin was determined using the microbroth dilution method. 13 The results were interpreted according to the criteria set by the CLSI. 13 
Genotyping of VRE
The genotypes of VREfm were determined using PCR methods as described previously. 14 
MLST
MLST for VREfm was performed as previously reported. 15 The alleles and sequence types (STs) were analysed and determined using the MLST database. Lu et al.
Enterococcus gallinarum Enterococcus faecium Enterococcus faecalis Enterococcus casseliflavus
Statistical analysis
Statistical analyses were executed using Stata software, version 10 (StataCorp, College Station, TX, USA). Continuous variables were described as mean+SD or median and range, and were compared using Student's t-test or the Mann-Whitney U-test. Categorical variables were compared using the x 2 test or, if the expected values were ,10, Fisher's exact test. Risk factors for mortality were identified using logistic regression. All relevant clinical and laboratory variables were first tested by univariate analysis. Variables with a P value ,0.25 and probable biological meaning were then put into the multivariate analysis. A stepwise model comparison and selection were used to determine the final model of multivariate analysis. All tests were two-tailed. A P value ,0.05 was considered statistically significant.
Results
During the 8 year study period, a total of 1985 patients developed Enterococcus bacteraemia and 232 patients (11.7%) had VRE bacteraemia. None of the 232 patients had ever developed VRE bacteraemia before the study period. Among the 232 patients with VRE bacteraemia, the cause was VREfm in 149 (64.2%), E. faecalis in 8 (3.4%), Enterococcus casseliflavus in 33 (14.2%) and Enterococcus gallinarum in 29 (12.5%). The yearly species distribution of the 232 blood VRE isolates during the study period is shown in Figure 1 . Among the enterococcal blood isolates, the prevalence of vancomycin resistance increased from 3.9% in 2003 to 18.9% in 2010 (P,0.001, x 2 test for trend) (Figure 2 ), and the increase was primarily due to VREfm (Figure 1) .
The clinical characteristics of the 149 patients with VREfm bacteraemia are shown in (Figure 3) . The 14 and 28 day mortality rates were 48.3% and 59.7%, respectively. Factors associated with 14 day mortality by univariate analysis are shown in Table 2 . In multivariate analysis, use of immunosuppressants, high Charlson comorbidity index and septic shock were associated with a higher 14 day mortality rate, while receipt of either daptomycin or linezolid and VRE bacteraemia caused by ST414 strains were independently associated with a lower 14 day mortality, with ORs of 0.31 (95% CI, 0.10-0.96) and 0.24 (95% CI, 0.06 -0.96), respectively (Table 3) . When 28 day mortality was considered, only a longer hospital stay prior to bacteraemia, thrombocytopenia and septic shock were associated with a higher mortality rate, with ORs of 1.02 (95% CI, 1.00-1.04), 3.23 (95% CI, 1.39 -7.54) and 9.08 (95% CI, 3.64 -22.65), respectively. Treatment with different effective antibiotics was not associated with either 14 or 28 day mortality.
Discussion
Our study showed there was a significant increase in vancomycin resistance among enterococcal blood isolates in our hospital from 2003 to 2010. Among the blood VRE isolates, 64.2% were VREfm and remained highly susceptible to daptomycin, linezolid and tigecycline, which suggested that these three antimicrobial agents might be the antibiotics of choice to treat VREfm infections. ST18 and ST414 were the two predominant strains in 2009 and 2010, respectively. Patients with VREfm bacteraemia who received daptomycin, linezolid or tigecycline showed no significant differences in 14 and 28 day mortality in the multivariate analysis. However, patients who had ST414 VREfm bacteraemia had a significantly lower 14 day mortality rate.
An increasing resistance rate to vancomycin among enterococcal isolates has been documented globally. 16, 17 Clonal spread of some epidemic VREfm strains belonging to clonal complex 17 (CC17) contributed to this increase. 7, 18 The four major STs among the VREfm isolates tested in our study-ST17, ST18, ST78 and ST414-all belong to CC17, which might explain the same increasing trends of vancomycin resistance in Taiwan. A previous study demonstrated that ST78 was the epidemic strain causing VRE infections in Taiwan in 2007. 19 However, it remains unclear whether the increase in vancomycin resistance over the following years was caused by monoclonal or polyclonal spread. 20, 21 Our study showed that which correlated temporally with the rapid increase in VREfm. This finding suggests that the clonal spread of ST18 and ST414 might play an important role in the rapid increase of VREfm bacteraemia. Furthermore, previous studies from Taiwan did not identify any VREfm isolates belonging to ST414, and our study is the first to document the presence of ST414 in Taiwan. ST414 was first reported in Australia in 2008, 22, 23 and then in China and Korea in 2009. 24, 25 However, no clinical characteristics were described in these studies. Our study showed that VREfm isolates of ST414 had a higher rate of susceptibility to minocycline compared with those of other STs, and was associated with a lower 14 day mortality. Whether the pathogenicity of VREfm ST414 differs from VREfm with other STs warrants further study. Although resistance to linezolid, daptomycin and tigecycline have been reported in VREfm isolates, 26, 27 our isolates remained highly susceptible to these antibiotics, with the exception of two Vancomycin-resistant E. faecium bacteraemia in Taiwan 2247 JAC ST18 strains (9.5%) that were intermediately resistant to tigecycline. Identified risk factors for mortality due to VRE bacteraemia include shock, non-line source, haemodialysis, mechanical ventilator use and malnutrition. 28, 29 Our study found that the use of immunosuppressants, a high Charlson comorbidity index and septic shock were associated with a higher 14 day mortality rate. These factors are all indicators of poor host conditions and the severity of VRE BSIs, and therefore are associated with a poor outcome. Our study also identified that patients receiving adequate treatment for their VREfm bacteraemia had a significantly better outcome, as would be expected. In contrast, the only three independent factors associated with all-cause 28 day mortality were a longer hospital stay prior to bacteraemia, thrombocytopenia and septic shock. Although previous studies used 28 day mortality as the study endpoint, we chose to use 14 day mortality because it may eliminate potential bias in assignment of the cause of death, which is particularly problematic in patients with many comorbid conditions. 5 This may explain why ST414 was associated with 14 day mortality but not 28 day mortality in our study.
In the present study, patients receiving either linezolid or daptomycin to treat VREfm bacteraemia had similar 14 day mortality rates. However, due to limitations of the study design and the small number of enrolled patients, the results were not conclusive. A randomized, controlled trial is needed to compare the efficacies of daptomycin and linezolid for VREfm bacteraemia.
There are several limitations in our study. First, this was a retrospective study and missing data, though minimal, still existed. Second, just under one-third of the VREfm isolates were not available for microbiological characterization, which may limit the interpretation of the results. Third, our study included patients with polymicrobial bacteraemia, which may limit the generalizability of our results to patients with monomicrobial VRE bacteraemia. However, the clinical and microbiological results were similar after excluding patients with polymicrobial bacteraemia from the analysis (data not shown).
In conclusion, our study found that the prevalence of VRE that cause bacteraemia is increasing in Taiwan. Among the VREfm isolates, the susceptibility rates to daptomycin, linezolid and tigecycline remain high. Clonal spread of VREfm belonging to ST18 and ST414 might have contributed to the increase in VRE. The ST of VREfm could be an important factor in determining the 14 day mortality of patients with VREfm bacteraemia.
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